These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34154424)

  • 1. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
    Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
    SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
    Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
    J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1.
    McNulty DE; Bonnette WG; Qi H; Wang L; Ho TF; Waszkiewicz A; Kallal LA; Nagarajan RP; Stern M; Quinn AM; Creasy CL; Su DS; Graves AP; Annan RS; Sweitzer SM; Holbert MA
    SLAS Discov; 2018 Jan; 23(1):34-46. PubMed ID: 28957646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
    Alnabulsi SM; Al-Shar'i NA
    Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
    [No Abstract]   [Full Text] [Related]  

  • 5. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
    Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
    Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
    Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
    Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
    Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
    Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
    Sun J; Shi F; Yang N
    ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of substrate methylation and inhibition of SMYD2.
    Ferguson AD; Larsen NA; Howard T; Pollard H; Green I; Grande C; Cheung T; Garcia-Arenas R; Cowen S; Wu J; Godin R; Chen H; Keen N
    Structure; 2011 Sep; 19(9):1262-73. PubMed ID: 21782458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
    Colón-Bolea P; Crespo P
    Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
    Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
    Sun J; Li Z; Yang N
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
    Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
    Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
    Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
    Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
    Xu S; Wu J; Sun B; Zhong C; Ding J
    Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
    Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
    Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
    Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
    Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.